Epicardial fat and osteoprotegerin – does a mutual relation exist? Pilot study


Authors: Markéta Sovová 1;  Eliška Sovová 2;  Jana Zapletalová 3;  Markéta Kaletová 2;  David Stejskal 4;  Milan Sova 5;  Michal Konečný 1;  Vlastimil Procházka 1;  Drahomíra Vrzalová 1;  Lea Zarivnijová 1
Authors‘ workplace: II. interní klinika – gastroenterologická a hepatologická LF UP a FN Olomouc 1;  Klinika tělovýchovného lékařství a kardiovaskulární rehabilitace LF UP a FN Olomouc 2;  Ústav lékařské biofyziky LF UP Olomouc 3;  Ústav lékařské chemie a biochemie LF UP Olomouc 4;  Klinika plicních nemocí a tuberkulózy LF UP a FN Olomouc 5
Published in: Vnitř Lék 2018; 64(4): 343-346
Category: Original Contributions

Overview

Introduction:
Epicardial fat (EPI) plays important role in development of metabolic and cardiovascular diseases. According to population studies EPI represents independent risk factor of cardiovascular diseases (CVD) and also for neoplasms. Osteoprotegerin (OPG) is a glycoprotein which have role in regulation of immune and cardiovascular systems. High serum levels of OPG are connected with high cardiovascular risk.

The aim of our study was to evaluate possible correlation between EPI and OPG level in asymptomatic relatives of patients with CVD.

Material and methods:
53 asymptomatic relatives (37 male) (median age 53 years) of patients with CVD (ischemic heart disease, cerebrovascular disease) were included. Physical examination and biochemistry analysis were performed. GE Vivid 7 (GE Medical) was used for echocardiography. EPI was measured according to guidelines using parasternal long axis in diastole as a space in front of right ventricle.

Results:
EPI was present in 46 subjects (86.8 %) with mean value of 2.91 mm. In 10 subjects was the amount of EPI > 5 mm. Spearmann correlation analysis found statistically significant correlation between EPI and OPG (r = 0.271; p = 0.05) and age (r = 0.500; p < 0.0001). We have not found correlation between EPI, glycaemia and level of insulin, glycated Hb, total, LDL, HDL cholesterol and triglycerides.

Conclusion:
We have found positive correlation between EPI and OPG. More studies are needed to confirm applicability of this correlation in risk stratification.

Key words:
cardiovascular risk – epicardial fat – osteoprotegerin


Sources

1. Piepoli MF, Hoes AW, Agewall S et al. [European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice]. 2016 European Guidelines on cardiovascular disease prevention in clinical practice. Dostupné z DOI: <http://www.escardio.org/guidelines-surveys/esc-guidelines/GuidelinesDocuments/guidelines-CVD-prevention.pdf>.

2. Shimabukuro M, Kozuka C, Taira S et al. Ectopic fat deposition and global cardiometabolic risk: new paradigm in cardiovascular medicine. J Med Invest 2013; 60(1–2): 1–14.

3. Bertaso AG, Bertol D, Duncan BB et al. Epicardial fat: definition, measurements and systematic review of main outcomes. Arq Bras Cardiol 2013; 101(1): e18-e28. Dostupné z DOI: <http://dx.doi.org/10.5935/abc.20130138>.

4. Cherian S, Lopaschuk GD, Carvalho E. Cellular cross- talk between epicardial adipose tissue and myocardium in relation to the pathogenesis of cardiovascular disease. Am J Physiol Endocrinol Metab 2012; 303(8): 937–949. Dostupné z DOI: <http://dx.doi.org/10.1152/ajpendo.00061.2012>.

5. Rosito GA, Massaro JM, Hoffmann U et al. Pericardial fat,visceral abdominal fat, cardiovascular disease risk factors and vascular calcification in a community based sample: the Framingham Heart Study. Circulation 2008; 117(5): 605–613. Dostupné z DOI: <http://dx.doi.org/10.1161/CIRCULATIONAHA.107.743062>.

6. Ding J, Hsu FC, Harris TB et al. The association of pericardial fat with incident coronary heart disease. The Multiethnic Study of Atherosclerosis (MESA). Am J Clin Nutr 2009; 90(3): 499–504. Dostupné z DOI: <http://dx.doi.org/10.3945/ajcn.2008.27358>.

7. Britton KA, Massaro JM, Murabito JM et al. Body fat distribution, incident cardiovascular disease, cancer, and all cause mortality. J Am Coll Cardiol 2013; 62(10): 921–925. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jacc.2013.06.027>.

8. Oikawa M, Owada T, Yamauchi H et al. Epicardial adipose tissue reflects the presence if coronary artery disease: comparison with abdominal visceral adipose tissue. Biomed Res Int 2015; 2015: 483982. Dostupné z DOI: <http://dx.doi.org/10.1155/2015/483982>.

9. Schoppet M, Preissner KT, Hofbauer LC. Rank ligand and osteoprotegerin: paracrine regulators of bone metabolism and vascular function. Atherioscler Thromb Vasc Biol 2002; 22(4): 549–553.

10. Simonet WS, Lacey DL, Dunstan CR et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997; 89(2): 309–319.

11. Hofbauer LC, Shui C, Riggs BL et al. Effects of immunosuppressants on receptor activator of NF- kappa B ligand and osteoprotegerin production by human osteoblastic and coronary artery smooth muscle cels. Biochem Biophys Res Commun 2001; 280(1): 334–339. Dostupné z DOI: <http://dx.doi.org/10.1006/bbrc.2000.4130>.

12. Kiechl S, Schett G, Wenning G et al. Osteoprotegerin in a risk factor for progressive atherosclerosis and cardiovascular disease. Circulation 2004; 109(18): 2175–2180. Dostupné z DOI: <http://dx.doi.org/10.1161/01.CIR.0000127957.43874.BB>.

13. Introduction: The American Diabetes Association’s (ADA) evidence-based practice guidelines, standards, and related recommendations and documents for diabetes care. Diabetes Care 2012; 35(Suppl 1): S1-S2. Dostupné z DOI: <http://dx.doi.org/10.2337/dc12-s001>.

14. Pierdomenico SD, Pierdomenico AM, Cuccurullo F et al. Meta-analysis of the relation of echocardiographic epicardial adipose tissue thickness and the metabolic syndrome. Am J Cardiol 2013; 111(1): 73–78. Dostupné z DOI: <http://dx.doi.org/10.1016/j.amjcard.2012.08.044>.

15. Xu Y, Cheng X, Hong K et al. How to interpret epicardial adipose tissue as a cause of coronary artery disease: a meta-analysis. Coron Artery Dis 2012; 23(4): 227–233. Dostupné z DOI: <http://dx.doi.org/10.1097/MCA.0b013e328351ab2c>.

16. Wu FZ, Chou JK, Wu MT et al. The relation of location-specific epicardial adipose tissue thickness and obstructive coronary artery disease: systemic review and meta-analysis of observational studies. BMC Cardiovasc Disord 2014; 14: 62. Dostupné z DOI: <http://dx.doi.org/10.1186/1471–2261–14–62>.

17. Prídavková D, Kantárová D, Lišková R et al. Význam epikardiálního tuku a obezitních parametrů při predikcii koronárnej choroby srdca. Vnitř Lék 2016; 62(4): 256–262.

18. Dey D, Nakazato R, Li D et al. Epicardial and thoracic fat- noninvasive measurement and clinical implications. Cardiovasc Diagn Ther 2012; 2(2): 85–93. Dostupné z DOI: <http://dx.doi.org/10.3978/j.issn.2223–3652.2012.04.03>.

19. Mahabadi AA, Berg MH, Lehmann N et al. Association of epicardial fat with cardiovascular risk factors and incident myocardial infarction in the general population: the Heinz Nixdorf Recall Study. J Am Coll Cardiol 2013; 61(13): 1388–1395. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jacc.2012.11.062>.

20. Jeong JW, Jeong MH, Yun KH et al. Echocardiographic epicardial fat thickness and coronary artery disease. Circ J 2007; 71(4): 536–539.

21. Mogelvang R, Pedersen AH, Bjerre M et al. Osteoprotegerin improved risk detection by traditional cardiovascular risk factors and hsCRP. Heart 2013; 99(2): 106–110. Dostupné z DOI: <http://dx.doi.org/10.1136/heartjnl-2012–302240>.

22. Pedersen S, Mogelvang R, Bjerre M et al. Osteoprotegerin predicts long term outcome in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention. Cardiology 2012; 123(1): 31–38. Dostupné z DOI: <http://dx.doi.org/10.1159/000339880>.

23. Lindberg S, Jensen JS, Hoffmann S et al. Osteoprotegerin levels change during STEMI and reflect cardiac function. Can J Cardiol 2014; 30(12): 1523–1528. Dostupné z DOI: <http://dx.doi.org/10.1016/j.cjca.2014.08.015>.

24. Oguz D, Unal H, Eroglu H et al. Aortic flow propagation velocity, epicardial fat thickness, aned osteoprotegerin level to predict subclinical atherosclerosis in patients with nonalcoholic fatty liver disease. Anatol J Cardiol 2016; 16(12): 974–979. Dostupné z DOI:

Labels
Diabetology Endocrinology Internal medicine

Article was published in

Internal Medicine

Issue 4

2018 Issue 4

Most read in this issue

This topic is also in:


Login
Forgotten password

Don‘t have an account?  Create new account

Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account